stockportfolio.pro
Stocks / GMRS vs RLMD
GMRS vs RLMD
GMR Solutions Inc. and Relmada Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| GMR Solutions Inc. (GMRS) | Relmada Therapeutics, Inc. (RLMD) | |
|---|---|---|
| Market cap | $0.7B | $0.7B |
| Revenue (latest FY) | $5.74B | $0 |
| Net income (latest FY) | $206.23M | $-57.39M |
| Revenue growth (5y CAGR) | 3.1% | — |
| Net margin | 3.6% | — |
| Return on equity | 101.0% | -66.3% |
| P/E ratio | 6.5 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 2 | 0 |
| Positive free cash flow | Yes | — |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open GMRS — free Open RLMD — freeFrequently asked questions
Which is bigger, GMRS or RLMD?
GMR Solutions Inc. is larger by market capitalization — $0.7B versus $0.7B.
Which grows faster, GMRS or RLMD?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.